<DOC>
	<DOCNO>NCT01926886</DOCNO>
	<brief_summary>This single arm , multicenter study evaluate safety assist subcutaneous administration Herceptin ( trastuzumab ) patient HER2-positive early breast cancer . Patients complete first 6 cycle intravenous Herceptin part ( neo ) adjuvant treatment eligible receive 12 cycle Herceptin study . For first 3 cycle , Herceptin administer intravenously ( 6 mg/kg ) hospital . The next 3 cycle , Herceptin ( 600 mg every 3 week ) administer subcutaneously via hand-held syringe train HCP hospital , last 6 cycle Herceptin administer subcutaneously via hand-held syringe train HCP patient 's home .</brief_summary>
	<brief_title>A Study Subcutaneous At Home Administration Herceptin ( Trastuzumab ) Patients With HER2-Positive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female male patient , &gt; /= 18 year age Histologically confirm nonmetastatic primary invasive adenocarcinoma breast HER2positive disease immunohistochemistry ( IHC ) 3+ situ hybridization ( ISH ) positive , line local reimbursement criterion determine local laboratory experienced/certified HER2expression test use accurate validate assay Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Hormonal therapy allow per institutional guideline Left ventricular ejection fraction ( LVEF ) &gt; /= 50 % measure echocardiography ( ECHO ) multiple gated acquisition ( MUGA ) scan prior first dose trastuzumab SC , , receive trastuzumab begin study , document result within acceptable limit cardiac assessment within 3 month prior enrolment Patients complete first 6 cycle trastuzumab IV part ( neo ) adjuvant treatment No evidence residual , locally recurrent metastatic disease completion surgery chemotherapy , ( neoadjuvant adjuvant ) Use concurrent curative radiotherapy permit History malignancy could affect compliance protocol interpretation result . Patients curatively treat carcinoma situ cervix basal cell carcinoma , patient curatively treated malignancy diseasefree least 5 year , eligible Patients severe dyspnea rest require supplementary oxygen therapy Patients concurrent serious disease may interfere plan treatment , include severe pulmonary conditions/illness Serious cardiac illness medical condition would preclude use trastuzumab , specifically : history document congestive heart failure ( CHF ) , highrisk uncontrolled arrhythmia , angina pectoris require medication , clinically significant valvular disease , evidence transmural infarction electrocardiogram ( ECG ) , diagnose poorly control hypertension Known infection human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Pregnant lactate woman Women childbearing potential male patient partner childbearing potential unable unwilling use adequate contraceptive measure study treatment Concurrent enrolment another clinical trial use investigational anticancer treatment , include hormonal therapy , bisphosphonate therapy immunotherapy , within 28 day prior first dose study treatment Known hypersensitivity trastuzumab , murine protein , excipients Herceptin include hyaluronidase , adhesive SC device , history severe allergic immunological reaction , e.g . difficult control asthma Inadequate bone marrow , hepatic renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>